Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
46-60 of 2352 results
Redx signs deal with Quay Pharma to manufacture clinical trial supplies for Porcupine inhibitor
Redx Pharma has entered into an agreement with Quay Pharma to manufacture the clinical trial supplies for Redx’s Porcupine inhibitor (RXC004), which has the potential to tackle hard-to-treat cancers, such as pancreatic, triple negative breast and head and neck cancers.
Contract Research & Services > Contract Services > News
Aeterna Zentaris announces two new licensing deals for Zoptrex
Ergomed announced that its co-development partner, Aeterna Zentarisc has signed two further licensing deals for Zoptrex.
Contract Research & Services > Contract Services > News
TaiGen out-licenses Taigexyn to Productos Cientificos for Latin American market
TaiGen Biotechnology Company has signed an exclusive licensing agreement with Mexican pharmaceutical firm Productos Científicos (PC) to develop and commercialize Taigexyn (nemonoxacin) in Latin America.
Contract Research & Services > Contract Services > News
Celsion, Zhejiang Hisun sign deal to develop GEN-1 immuno-oncology therapy
Celsion has signed a long-term Technology Transfer, Manufacturing and Commercial Supply Agreement with Zhejiang Hisun Pharmaceutical to pursue an expanded partnership for the technology transfer relating to the clinical and commercial manufacture and supply of GEN-1, Celsion's gene mediated, IL-12 immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of the world after all necessary regulatory approvals are in effect.
Contract Research & Services > Contract Services > News
Juno Therapeutics forms multiple myeloma partnership with MSK and Eureka Therapeutics
Juno Therapeutics has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.
Contract Research & Services > Contract Services > News
Amgen secures rights to Advaxis’ cancer immunotherapy treatment
By PBR Staff Writer
Amgen has acquired global rights to a preclinical cancer immunotherapy treatment developed by Advaxis.
Contract Research & Services > Contract Services > News
Merck to offer Provantage end-to-end development and manufacturing services to Y-mAbs
Merck will provide its Provantage End-to-End development and manufacturing services to Y-mAbs Therapeutics in support of Y-mAbs' monoclonal antibody in late stage clinical development.
Contract Research & Services > Contract Services > News
Orexigen signs commercialization deal with Laboratorios Farmace´utico for Mysimba in Spain
Orexigen Therapeutics' wholly owned subsidiary Orexigen Therapeutics Ireland and Laboratorios Farmacéuticos Rovi, S.A. (ROVI) have executed a commercialization and distributorship agreement for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Spain.
Contract Research & Services > Contract Services > News
Profil Institute, HighTide Biopharmaceutical partner to develop new therapies for diabetes and NAFLD/NASH
Profil Institute for Clinical Research, a science-driven clinical research organization (CRO) focused exclusively on metabolic diseases, announced today a strategic master services agreement with Shenzhen HighTide Biopharmaceutical, a subsidiary of Shenzhen Hepalink Pharmaceutical.
Contract Research & Services > Contract Services > News
Almirall, Sun Pharma sign license deal to develop tildrakizumab for psoriasis in Europe
Sun Pharma, Sun Pharmaceutical Industries and its subsidiaries or associate companies, and Almirall have signed a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe.
Contract Research & Services > Contract Services > News
Kite Pharma announces exclusive license with NIH for anti-CD19 CAR product candidate
Kite Pharma has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies.
Contract Research & Services > Contract Services > News
Trek Therapeutics acquires two antiviral inhibitors from Vertex Pharmaceuticals
Trek Therapeutics has acquired the worldwide development and commercialization rights to treat infectious disease with lomibuvir (VX-222), a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib (VX-497), an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties from Vertex Pharmaceuticals.
Contract Research & Services > Contract Services > News
Chugai, Galderma sign license deal for nemolizumab
Chugai Pharmaceutical and Galderma Pharma have entered into a global license agreement for “nemolizumab” (CIM331) the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patients.
Contract Research & Services > Contract Services > News
Sapience Therapeutics signs license deal with Columbia University for novel cancer treatment
Sapience Therapeutics has entered into an exclusive license agreement with Columbia University to develop a first-in-class cancer treatment, which the Company refers to as ST-36.
Contract Research & Services > Contract Services > News
Stellar Biotechnologies, Neovacs establish new company in France
Stellar Biotechnologies and Neovacs announced the formation of Neostell, a simplified stock corporation headquartered in France, to carry out the business of the companies' joint venture, previously announced on May 11, 2016, to manufacture and sell conjugated therapeutic vaccines using Stellar's Keyhole Limpet Hemocyanin (KLH).
Contract Research & Services > Contract Services > News
46-60 of 2352 results